The molecular pathogenesis of Paget disease of bone

Expert Reviews in Molecular Medicine

Volumn 9, Issue 27, 2007, Pages 1-13

  Layfield, Robert ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BISPHOSPHONIC ACID DERIVATIVE; HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN P62; RECOMBINANT OSTEOPROTEGERIN; SEQUESTOSOME 1; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

BONE REMODELING; CLINICAL FEATURE; DRUG MECHANISM; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC DISORDER; GENETIC RISK; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOSARCOMA; PAGET BONE DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS INFECTION;

BONE AND BONES; BONE REMODELING; BONE RESORPTION; HUMANS; MUTATION; NF-KAPPA B; OSTEITIS DEFORMANS; OSTEOBLASTS; OSTEOCLASTS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; VIRAL PHYSIOLOGY;

EID: 34848912628     PISSN: 14623994     EISSN: 14623994     Source Type: Journal    
DOI: 10.1017/S1462399407000464     Document Type: Review

References (90)

1. Roberts, S. (1989) Sir James Paget - the Rise of Clinical Surgery, Royal Society of Medicine Services Ltd, London
2. Rogers, J., Jeffrey, D.R. and Watt, I. (2002) Paget's disease in an archeological population. J Bone Miner Res 17, 1127-1134
3. Cooper, C. et al. (1999) The epidemiology of Paget's disease in Britain: is the prevalence decreasing? J Bone Miner Res 14, 192-197
4. Daroszewska, A. and Ralston, S.H. (2005) Genetics of Paget's disease of bone. Clin Sci (Lond) 109, 257-263
5. Kanis, J.A. (1992) Pathophysiology and Treatment of Paget's Disease of Bone, Martin Dunitz, London
6. van Staa, T.P. et al. (2002) Incidence and natural history of Paget's disease of bone in England and Wales. J Bone Miner Res 17, 465-471
7. Huvos, A.G. (1986) Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer 57, 1442-1449
8. Reddy, S.V. et al. (1999) Cell biology of Paget's disease. J Bone Miner Res 14, Suppl 2, 3-8
9. Gardner, M.J., Guyer, P.B. and Barker, D.J. (1978) Radiological prevalence of Paget's disease of bone in British migrants to Australia. Br Med J 1, 1655-1657
10. Siris, E.S. (1994) Epidemiological aspects of Paget's disease: Family history and relationship to other medical conditions. Semin Arthritis Rheum 23, 222-225
11. Sofaer, J.A., Holloway, S.M. and Emery, A.E. (1983) A family study of Paget's disease of bone. J Epidemiol Community Health 37, 226-231
12. Morales-Piga, A.A. et al. (1995) Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res 10, 663-670
13. Hocking, L. et al. (2000) Familial Paget's disease of bone: Patterns of inheritance and frequency of linkage to chromosome 18q. Bone 26, 577-580
14. Haslam, S.I. et al. (1998) Paget's disease of bone: Evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res 13, 911-917
15. Layfield, R. and Hocking, L.J. (2004) SQSTM1 and Paget's disease of bone. Calcif Tissue Int 75, 347-357
16. Watts, G.D. et al. (2004) Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 36, 377-381
17. Duran, A. et al. (2004) The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6, 303-309
18. Teitelbaum, S.L. and Ross, F.P. (2003) Genetic regulation of osteoclast development and function. Nat Rev Genet 4, 638-649
19. Laurin, N. et al. (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70, 1582-1588
20. Hocking, L.J. et al. (2002) Domain specific mutations in Sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 11, 2735-2739
21. Johnson-Pais, T.L. et al. (2003) Three novel mutations in SQSTM1 identified in familial Paget's disease of bone. J Bone Miner Res 18, 1748-1753
22. Good, D.A. et al. (2004) Identification of SQSTM1 mutations in familial Paget's disease in Australian pedigrees. Bone 35, 277-282
23. Beyens, G. et al. (2004) Evaluation of the role of the SQSTM1 gene in sporadic Belgian patients with Paget's disease. Calcif Tissue Int 75, 144-152
24. Eekhoff, E.W. et al. (2004) Familial Paget's disease in The Netherlands: occurrence, identification of new mutations in the sequestosome 1 gene, and their clinical associations. Arthritis Rheum 50, 1650-1654
25. Falchetti, A. et al. (2004) Two novel mutations at exon 8 of Sequestosome 1 gene (SQSTM1) in an Italian serie of patients affected by Paget's disease of bone (PDB). J Bone Miner Res 19, 1013-1017
26. Hocking, L.J. et al. (2004) Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: Genotype phenotype correlation, functional analysis and structural consequences. J Bone Miner Res 19, 1122-1127
27. Beyens, G. et al. (2006) Identification and molecular characterization of a novel splice-site mutation (G1205C) in the SQSTM1 gene causing Paget's disease of bone in an extended American family. Calcif Tissue Int 79, 281-288
28. Rea, S.L. et al. (2006) A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signalling and Paget's disease of bone with a severe phenotype. J Bone Miner Res 21, 1136-1145
29. Collet, C. et al. (2007) Paget's disease of bone in the French population: Novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations. J Bone Miner Res 22, 310-317
30. Hughes, A.E. et al. (2000) Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 24, 45-48
31. Whyte, M.P. and Hughes, A.E. (2002) Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 17, 26-29
32. Nakatsuka, K., Nishizawa, K. and Ralston, S.H. (2003) Phenotypic characterisation of early onset Paget's disease of bone caused by a 27 bp duplication in the TNFRSF11A gene. J Bone Miner Res 18, 1381-1385
33. Whyte, M.P. et al. (2002) Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 347, 175-184
34. Cundy, T. et al. (2002) A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 11, 2119-2127
35. Asai, T. et al. (2002) VCP (p97) regulates NFkappaB signaling pathway, which is important for metastasis of osteosarcoma cell line. Jpn J Cancer Res 93, 296-304
36. Hsu, H. et al. (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96, 3540-3545
37. Galibert, L. et al. (1998) The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 273, 34120-341277
38. Ye, H. et al. (2002) Distinct molecular mechanism for initiating TRAF6 signalling. Nature 418, 443-447
39. Deng, L. et al. (2000) Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351-361
40. Chen, Z.J. (2005) Ubiquitin signalling in the NF-kappaB pathway Nat Cell Biol 7, 758-765
41. Andersen, K.M., Hofmann, K. and Hartmann-Petersen, R. (2005) Ubiquitin-binding proteins: Similar, but different. Essays Biochem 41, 49-67
42. Kanayama, A. et al. (2004) TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell 15, 535-548
43. Jimi, E. et al. (2004) Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10, 617-624
44. Yip, K.H. et al. (2006) p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: A new insight into the pathogenesis of Paget's disease of bone. Am J Pathol 169, 503-514
45. Raasi, S. et al. (2005) Diverse polyubiquitin interaction properties of ubiquitin-associated domains. Nat Struct Mol Biol 12, 708-714
46. Vadlamudi, R.K. et al. (1996) p62, a phosphotyrosine-independent ligand of the SH2 domain of p561ck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271, 20235-20237
47. Layfield, R. et al. (2006) p62 mutations, ubiquitin recognition and Paget's disease of bone. Biochem Soc Trans 34, 735-737
48. Cavey, J.R. et al. (2005) Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J Bone Miner Res 20, 619-624
49. Cavey, J.R. et al. (2006) Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif Tissue Int 78, 271-277
50. Wooten, M.W. et al. (2005) The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J Biol Chem 280, 35625-35629
51. Takayanagi, H. et al. (2000) T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature 408, 600-605
52. Menaa, C. et al. (2000) Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 105, 1833-1938
53. Hofbauer, L.C. and Heufelder, A.E. (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology J Mol Med 79, 243-253
54. Martini, G. et al. (2007) Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. Bone 40, 457-463
55. Halawani, D. and. Latterich, M. (2006) p97: The cell's molecular purgatory? Mol Cell 22, 713-717
56. Weihl, C.C. et al. (2006) Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Hum Mol Genet 15, 189-199
57. Dai, R.M. et al. (1998) Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem 273, 3562-3573
58. Layfield, R. et al. (2001) The ubiquitin protein catabolic disorders. Neuropathol Appl Neurobiol 27, 171-179
59. Reddy, S.V. (2006) Etiologic factors in Paget's disease of bone. Cell Mol Life Sci 63, 391-398
60. Harvey, L. et al. (1982) Ultrastructural features of the osteoclasts from Paget's disease of bone in relation to a viral etiology. J Clin Pathol 35, 771-779
61. Mills, B.G. and Singer, F.R. (1976) Nuclear inclusions in Paget's disease of bone. Science 194, 201-202
62. Mills, B.G. et al. (1984) Evidence for both respiratory synctial virus and measles virus antigens in the osteoclasts of patients with Paget's disease of bone. Clin Orthop Relat Res 183, 303-311
63. Rebel, A. et al. (1980) Bone tissue in Paget's disease of bone. Ultrastructure and immunocytology. Arthritis Rheum 23, 1104-1144
64. Reddy, S.V. et al. (1999) Measles virus nucleocapsid transcript expression is not restricted to the osteoclast lineage in patients with Paget's disease of bone. Exp Hematol 27, 1528-1532
65. Friedrichs, W.E. et al. (2002) Sequence analysis of measles virus nucleocapsid transcripts in patients with Paget's disease. J Bone Miner Res 17, 145-151
66. Helfrich, M.H. et al. (2000) A negative search for a paramyxoviral etiology of Paget's disease of bone: Molecular, immunological, and ultrastructural studies in UK patients. J Bone Miner Res 15, 2315-2329
67. Ralston, S.H. et al. (2007) Multicenter blinded analysis of RT-PCR detection methods for paramyoviruses in relation to Paget's disease of bone. J Bone Miner Res 22, 569-577
68. Kurihara, N. et al. (2000) Osteoclasts expressing the measles virus nucleocapsid gene display a pagetic phenotype. J Clin Invest 105, 607-614
69. Menaa, C. et al. (2000) 1,25-Dihydroxyvitamin D3 hypersensitivity of osteoclast precursors from patients with Paget's disease. J Bone Miner Res 15, 228-236
70. Kurihara, N. et al. (2004) Role of TAFII-17, a VDR binding protein, in the increased osteoclast formation in Paget's disease. J. Bone Miner Res 19, 1154-1164
71. Kurihara, N. et al. (2006) Experimental models of Paget's disease. J Bone Miner Res 21, Suppl 2, 55-57
72. Kurihara, N. et al. (2006) Expression of the measles virus nucleocapsid protein in osteoclasts in vivo induces Paget's disease like bone lesions in mice. J Bone Miner Res 21, 446-455
73. Mee, A.P. et al. (1998) Detection of canine distemper virus in 100% of Paget's disease samples by in situ reverse transcriptase polymerase chain reaction. Bone 23, 171-175
74. Selby, P.L., Davies, M. and. Mee, A.P. (2006) Canine distemper virus induces human osteoclastogenesis through NF-kappB and sequestosome1/p62 activation. J Bone Miner Res 21, 1750-1756
75. Cundy, T. (2006) Is the prevalence of Paget's disease of bone decreasing? J Bone Miner Res 21, Suppl 2, 9-13
76. Bolland, M.J. et al. (2007) Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res 22, 411-415
77. Siris, E.S. (1994) Epidemiological aspects of Paget's disease: Family history and relationship to other medical conditions. Semin Arthritis Rheum 23, 222-225
78. Lever, J.H. (2002) Paget's disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: A speculative hypothesis. Bone 31, 434-436
79. Aono, J. et al. (2003) Activation of Nrf2 and accumulation of ubiquitinated A170 by arsenic in osteoblasts. Biochem Biophys Res Commun 305, 271-277
80. Coxon, F.P., Thompson, K. and. Rogers, M.J. (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6, 307-312
81. Corrado, A., Santoro, N. and Cantatore, F.P. (2007) Extra-skeletal effects of bisphosponates. Joint Bone Spine 74, 32-38
82. Hoskins, D. (2006) Pharmacological therapy of Paget's and other metabolic bone diseases. Bone 38, Suppl 2, 3-7
83. Langston, A.L. et al. (2007) Clinical determinants of quality of life in Paget's disease of bone. Calcif Tissue Int 80, 1-9
84. Vaananen, K. (2005) Mechanism of osteoclast mediated bone resorption-rationale for the design of new therapeutics. Adv Drug Deliv Rev 57, 959-971
85. Tat, S.K. et al. (2006) OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone 39, 706-715
86. McClung, M.R. et al. (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354, 821-831
87. Cundy, T. et al. (2005) Recombinant osteoprotegerin for juvenile Paget's disease. N Engl J Med 353, 918-923
88. Leach, R.J. et al. (2006) Clinical and cellular phenotypes associated with Sequestosome 1 (SQSTM1) mutations. J Bone Miner Res 21, Suppl 2, 45-50
89. Morisette, J., Laurin, N. and. Brown, J.P. (2006) Sequestosome 1: mutation frequencies, haplotypes and phenotypes in familial Paget's disease of bone. J Bone Miner Res 21, Suppl 2, 38-44
90. Kurihara, N. et al. (2007) Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest 117, 133-142